These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 8033063)
1. Downregulation of lymphocyte mitogenesis by breast cancer-associated p43. Rosen HR; Ausch C; Reiner G; Reinerova M; Svec J; Tüchler H; Schiessel R; Moroz C Cancer Lett; 1994 Jul; 82(1):105-11. PubMed ID: 8033063 [TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive activity of lymphocyte mitogenesis by breast cancer-associated p43. Reinerová M; Veselovská Z; Ausch C; Rosen HR Neoplasma; 1996; 43(6):363-6. PubMed ID: 8996559 [TBL] [Abstract][Full Text] [Related]
3. Activated lymphocytes from breast cancer patients express the characteristics of type 2 helper cells--a possible role for breast cancer-associated p43. Rosen HR; Ausch C; Reinerova M; Zaspin E; Renner K; Rosen AC; Schiessel R; Moroz C Cancer Lett; 1998 May; 127(1-2):129-34. PubMed ID: 9619868 [TBL] [Abstract][Full Text] [Related]
4. Immunosuppression by breast cancer associated p43-effect of immunomodulators. Rosen HR; Ausch C; Reiner G; Reinerova M; Svec J; Tüchler H; Schiessel R; Moroz C Breast Cancer Res Treat; 1996; 41(2):171-6. PubMed ID: 8944335 [TBL] [Abstract][Full Text] [Related]
5. Identification of women with early breast cancer by analysis of p43-positive lymphocytes. Auerbach L; Hellan M; Stierer M; Rosen AC; Ausch C; Obwegeser R; Kubista E; Wolf G; Rosen HR; Panzer S Br J Cancer; 1999 May; 80(5-6):874-8. PubMed ID: 10360668 [TBL] [Abstract][Full Text] [Related]
6. Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer. Rosen HR; Moroz C; Reiner A; Reinerova M; Stierer M; Svec J; Schemper M; Jakesz R Breast Cancer Res Treat; 1992; 24(1):17-26. PubMed ID: 1463868 [TBL] [Abstract][Full Text] [Related]
7. Expression of p43 associated placental isoferritin (PLF) correlates inversely with cell growth in breast cancer cell lines MCF-7 and T47-D. Reinerová MH; Rosen HR; Veselovská Z; Stierer M; Svec J Neoplasma; 1993; 40(3):147-51. PubMed ID: 8350961 [TBL] [Abstract][Full Text] [Related]
8. The immunosuppressive human placental ferritin subunit p43 is produced by activated CD4+ lymphocytes. Garty B; Kaminsky E; Moroz C Clin Diagn Lab Immunol; 1995 Mar; 2(2):225-6. PubMed ID: 7697533 [TBL] [Abstract][Full Text] [Related]
9. Expression of p43 in breast cancer tissue, correlation with prognostic parameters. Rosen HR; Moroz C; Reiner A; Stierer M; Svec J; Reinerova M; Schemper M; Jakesz R Cancer Lett; 1992 Oct; 67(1):35-45. PubMed ID: 1423243 [TBL] [Abstract][Full Text] [Related]
10. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412 [TBL] [Abstract][Full Text] [Related]
11. Roles of reactive nitrogen intermediates and transforming growth factor-beta produced by immunosuppressive macrophages in the expression of suppressor activity against T cell proliferation induced by TCR stimulation. Shimizu T; Cai S; Tomioka H Cytokine; 2005 Apr; 30(1):7-13. PubMed ID: 15784407 [TBL] [Abstract][Full Text] [Related]
12. Enhanced expression of the immunoregulator, p43-placental isoferritin, in Down's syndrome placentae and fetal kidneys. Maymon R; Jauniaux E; Moroz C Mol Hum Reprod; 2002 Dec; 8(12):1125-8. PubMed ID: 12468646 [TBL] [Abstract][Full Text] [Related]
13. Localization of p43 placental isoferritin in human maternal-fetal tissue interface. Maymon R; Jauniaux E; Greenwold N; Moroz C Am J Obstet Gynecol; 2000 Mar; 182(3):670-4. PubMed ID: 10739528 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Liyanage UK; Moore TT; Joo HG; Tanaka Y; Herrmann V; Doherty G; Drebin JA; Strasberg SM; Eberlein TJ; Goedegebuure PS; Linehan DC J Immunol; 2002 Sep; 169(5):2756-61. PubMed ID: 12193750 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the immunosuppressive properties of milk growth factor and transforming growth factors beta 1 and beta 2. Stoeck M; Ruegg C; Miescher S; Carrel S; Cox D; Von Fliedner V; Alkan S J Immunol; 1989 Nov; 143(10):3258-65. PubMed ID: 2530275 [TBL] [Abstract][Full Text] [Related]
16. Placental isoferritin-associated p43 in pregnancy and breast cancer. Minireview. Rosen HR Neoplasma; 1996; 43(6):357-62. PubMed ID: 8996558 [TBL] [Abstract][Full Text] [Related]
17. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469 [TBL] [Abstract][Full Text] [Related]
18. Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Boniface JD; Poschke I; Mao Y; Kiessling R Int J Cancer; 2012 Jul; 131(1):129-39. PubMed ID: 21823123 [TBL] [Abstract][Full Text] [Related]
19. Purinergic modulation of T-lymphocyte activation: differential susceptibility of distinct activation steps and correlation with intracellular 3',5'-cyclic adenosine monophosphate accumulation. DosReis GA; Nóbrega AF; de Carvalho RP Cell Immunol; 1986 Aug; 101(1):213-31. PubMed ID: 3017570 [TBL] [Abstract][Full Text] [Related]
20. Peripheral blood lymphocytes from patients with cancer lack interleukin-2 receptors. Hakim AA Cancer; 1988 Feb; 61(4):689-701. PubMed ID: 2962732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]